Aflac Incorporated, a leader in supplemental health and life insurance, is noted for its strong presence in both Japan and the U.S. Investors are advised to consider its B+ fundamental rating and a consistent track record. The stock shows promise with robust returns on equity and assets.
Aflac has maintained a solid B+ rating, with strong performances shown in critical financial metrics such as return on equity and assets.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 4 | |
| Return on Assets | 4 | |
| Debt to Equity | 3 | |
| Price to Earnings | 2 | |
| Price to Book | 2 |
The historical scores indicate a steady performance over recent reviews with no drastic changes in fundamental strengths.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-07-15 | 3 | 4 | 4 | 4 | 3 | 2 | 2 |
| Previous | 0 | 4 | 4 | 4 | 3 | 2 | 2 |
The current price targets reflect a balanced view among analysts, with the consensus leaning towards a "Hold" rating.
| High | Low | Median | Consensus |
|---|---|---|---|
| 105 | 98 | 101.5 | 101.5 |
Analyst sentiment suggests cautious optimism, with more analysts recommending holding over buying or selling.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 10 | |
| Hold | 16 | |
| Sell | 4 | |
| Strong Sell | 0 |
Aflac Incorporated appears to present a stable investment opportunity, with solid fundamental metrics and a consistent rating. Despite economic fluctuations, the company's diversified product range in Japan and the U.S. supports its resilience. Current analyst sentiments suggest a balanced outlook, though potential investors should remain attentive to market dynamics. Overall, while there are no overwhelming signals to buy, the stock remains a valuable component for portfolios emphasizing stability.